Evidence map›Paper›PMID 38646337›Full record

ArticleCureus2024

Evaluation of Steroid Pulse Therapy Responsiveness in Myelin-Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis.

Yasuyuki Takai, Akiko Yamagami, Mayumi Iwasa, Kenji Inoue, Masato Wakakura, Toshiyuki Takahashi, Keiko Tanaka

Open access · diamondAbstract read
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Yasuyuki TakaiDepartment of Ophthalmology, Inouye Eye Hospital, Tokyo, JPN.
Akiko YamagamiDepartment of Ophthalmology, Inouye Eye Hospital, Tokyo, JPN.
Mayumi IwasaDepartment of Ophthalmology, Inouye Eye Hospital, Tokyo, JPN.
Kenji InoueDepartment of Ophthalmology, Inouye Eye Hospital, Tokyo, JPN.
Masato WakakuraDepartment of Ophthalmology, Inouye Eye Hospital, Tokyo, JPN.
Toshiyuki TakahashiDepartment of Neurology, Tohoku University Graduate School of Medicine, Sendai, JPN.
Keiko TanakaDepartment of Animal Model Development, Brain Research Institute, Niigata University, Niigata, JPN.
Inouye Eye Hospital · JPNiigata University · JPTohoku University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMyelin-oligodendrocyte glycoprotein antibody-positive optic neuritis (MOGON) is usually responsive to the steroid, but, for some patients, steroid pulse therapy alone may be inadequate. This study aimed to investigate the factors predicting the response to steroid pulse therapy in MOGON.

methodsThis study included 17 patients (24 eyes) with MOGON, who received single steroid pulse therapy as initial treatment. Best corrected visual acuity (BCVA) and mean deviation (MD) values after treatment were examined concerning findings at onset.

resultsNo correlation was found between BCVA at onset and after treatment, but a correlation was observed between MD values at onset and after treatment (correlation coefficient 0.48, p=0.01, Spearman's rank correlation coefficient). Age, gender, duration from onset to treatment, magnetic resonance imaging findings, and optical coherence tomography findings did not affect visual function after treatment.

conclusionsSevere visual field impairment at onset may indicate that additional treatment may be necessary.

Indexed as

myelin-oligodendrocyte glycoprotein antibodyoptic neuritissteroidsteroid pulse therapyvisual field defect

Identifiers

PMID38646337
PMCPMC11032426
OpenAlexW4393092456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.